RNS Number : 4291J GSK PLC 20 May 2025

GSK plc (the 'Company')Transaction notification

Details of PDMR/person closely associated with them ('PCA')		
Name	Dr Hal Barron	
Position/status	Non-Executive Director	
Initial notification/ amendment	Initial notification	
	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
Name	GSK plc	
LEI	5493000HZTVUYLO1D	793
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
Description of the financial instrument	American Depositary S ISIN: US37733W2044	hares ('ADSs')
Nature of the transaction	'	ADSs within Dr Barron's GSK Executive Plan account following the reinvestment of
Price(s) and volume(s	Price(s)	Volume(s)
	37.6400	3,449.923
Aggregated information	N/A (single transaction)	
Aggregated volume Price		
Date of the transaction	2025-05-16	
Place of the transaction	New York Stock Excha	inge (XNYS)
	Name Position/status Initial notification/amendment Details of the issuer auctioneer or auction Name LEI Details of the transa (ii) each type of transaction(s) has b Description of the financial instrument Nature of the transaction Price(s) and volume(s) Aggregated information Aggregated volume Price Date of the transaction Place of the	Name Dr Hal Barron Position/status Non-Executive Director Initial notification/ amendment Initial notification Details of the issuer, emission allowance auctioneer or auction monitor Name GSK plc LEI 5493000HZTVUYLO1D Details of the transaction(s): section to be (ii) each type of transaction; (iii) each date transaction(s) has been conducted Description of the financial instrument ISIN: US37733W2044 Nature of the transaction Supplemental Savings Idividends Price(s) and volume(s) Price(s) 37.6400 Aggregated information Aggregated volume Price Date of the transaction Place of the New York Stock Excha

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	GSK plc

I-V	151	THE STATE OF THE S		
b)	LEI	5493000HZTVUYLO1D793		
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
a)	Description of the financial instrument	American Depositary ISIN: US37733W2044	,	
b)		Acquisition of ADSs v following the reinvestn	vithin Dr Barron's GSK 401(k) pla nent of dividends	n account
c)	Price(s) and volume(s)	Price(s) 37.6400	Volume(s) 87	
d)	information	N/A (single transactio	n)	
	Aggregated volume Price			
e)	Date of the transaction	2025-05-16		
f)	Place of the transaction	New York Stock Exchange (XNYS)		

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	James Ford	
b)	Position/status	SVP and Group General Counsel	, Legal and Compliance
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	American Depositary Shares ('AD ISIN: US37733W2044	OSs')
b)	Nature of the transaction	Acquisition of notional ADSs with Supplemental Savings Plan accordividends	
c)	Price(s) and volume(s)	Price(s) 37.6400	Volume(s) 64.195
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the	2025-05-16	

	transaction	
f)	Place of the transaction	New York Stock Exchange (XNYS)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHSEAFSSEISEFI